Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis

Robert J Commons, Julie A Simpson, James Watson, Nicholas J White, Ric N Price, Robert J Commons, Julie A Simpson, James Watson, Nicholas J White, Ric N Price

Abstract

Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate weeks to months following initial infection. Malaria recurrences caused by relapses are an important cause of morbidity and source of transmission. To estimate the proportions of P. vivax malaria recurrences caused by relapses in different geographical locations, we systematically reviewed clinical efficacy studies of uncomplicated P. vivax malaria, in which patients were randomized to treatment with or without radical cure primaquine regimens and were followed up for 1 year. The minimum proportion of recurrences caused by relapses was estimated for each study site by assuming primaquine prevented all relapses and did not augment blood-stage efficacy. Of the 261 studies identified, six were eligible enrolling 4,092 patients from 14 treatment arm comparisons across seven countries. Of the 2,735 patients treated with primaquine, 24.3% received low dose (2.5 to < 5.0 mg/kg total) and 75.7% received high-dose primaquine (≥ 5.0 mg/kg total). The overall pooled incidence rate ratio of P. vivax relapses for patients treated with primaquine versus no primaquine was 0.15 (95% CI: 0.10-0.21; I 2 = 83.3%), equating to a minimum of 79% of recurrences attributable to relapse. Country-specific incidence rate ratios ranged from 0.05 (95% CI: 0.01-0.34; one estimate) in Pakistan to 0.34 in Nepal (95% CI: 0.12-0.83; one estimate) and Afghanistan (95% CI: 0.22-0.51; three estimates). Relapses account for a very high proportion of recurrent infections following schizontocidal treatment of acute P. vivax malaria across diverse geographic locations. This emphasizes the importance of implementing hypnozoitocidal treatment.

Figures

Figure 1.
Figure 1.
Flow diagram. Reasons for study exclusion are detailed in Supplemental File 2.
Figure 2.
Figure 2.
Pooled estimates of the incidence rate ratios of P. vivax recurrences within 365 days of follow-up comparing treatment with primaquine with no primaquine by total primaquine dose administered (low dose 2.5 to < 5 mg/kg, high dose ≥ 5 mg/kg). AL = artemether–lumefantrine; CQ = chloroquine; DP = dihydroartemisinin–piperaquine; IRR = incidence rate ratio. * Blood schizontocidal treatment.
Figure 3.
Figure 3.
Pooled estimates of incidence rate ratios of P. vivax recurrences within 365 days of follow-up comparing treatment with primaquine with no primaquine by country. AL = artemether–lumefantrine; CQ = chloroquine; DP = dihydroartemisinin–piperaquine; IRR = incidence rate ratio *Blood schizontocidal treatment.

References

    1. Battle KE, et al. 2019. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study. Lancet 394: 332–343.
    1. White NJ, 2002. The assessment of antimalarial drug efficacy. Trends Parasitol 18: 458–464.
    1. Commons RJ, et al. 2018. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis 18: 1025–1034.
    1. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11: 280.
    1. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN, 2012. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Adv Parasitol 80: 271–300.
    1. Imwong M, et al. 2007. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927–933.
    1. Price RN, Auburn S, Marfurt J, Cheng Q, 2012. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol 28: 522–529.
    1. Robinson LJ, et al. 2015. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med 12: e1001891.
    1. Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, Cromer D, Davenport MP, 2015. Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis 9: e0003595.
    1. White NJ, 2011. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10: 297.
    1. Stijnen T, Hamza TH, Ozdemir P, 2010. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 29: 3046–3067.
    1. Spittal MJ, Pirkis J, Gurrin LC, 2015. Meta-analysis of incidence rate data in the presence of zero events. BMC Med Res Methodol 15: 42.
    1. Chu CS, et al. 2018. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis 67: 1543–1549.
    1. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, Rowland M, 2008. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One 3: e2861.
    1. Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NPJ, White NJ, Woodrow CJ, 2017. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. Am J Trop Med Hyg 97: 1782–1787.
    1. Abreha T, et al. 2017. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med 14: e1002299.
    1. Taylor WRJ, et al. 2019. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet 394: 929–938.
    1. Rijal KR, et al. 2019. Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal. J Infect Dis 220: 448–456.
    1. Taylor AR, et al. 2019. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun 10: 5595.
    1. Nelwan EJ, et al. 2015. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med 13: 294.
    1. Sutanto I, et al. 2013. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 57: 1128–1135.
    1. Schmidt LH, Fradkin R, Vaughan D, Rasco J, 1977. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg 26: 1116–1128.
    1. Baird JK, et al. 2018. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria. JAMA Netw Open 1: e181449.
    1. WHO , 2015. Guidelines for the Treatment of Malaria, 3rd edition Geneva, Switzerland: World Health Organization.
    1. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS, 2017. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19: 69–76.
    1. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 1680–1685.
    1. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ, 1994. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169: 932–935.
    1. World Health Organization , 2018. World Malaria Report 2018. Geneva, Switzerland: WHO.
    1. Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, Penpitchaporn P, Chu CS, Nosten F, Domingo GJ, 2019. Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg 100: 213–221.
    1. Chu CS, et al. 2018. Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria. Clin Infect Dis 68: 1311–1319.
    1. Lacerda MVG, et al. 2019. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 380: 215–228.
    1. Llanos-Cuentas A, et al. 2019. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 380: 229–241.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi